Genefitletics launches Prognora, an AI-powered prognostic platform detecting metabolic & oral diseases 7–10 years before diagnosis

Genefitletics, a biophysics-led preventive health company founded in 2020, has announced the launch of Prognora, an AI-powered prognostic platform built specifically on Indian molecular data. The platform detects molecular and microbial abnormalities up to 7 to 10 years before clinical diagnosis. Available from 26 October 2026 both direct-to-consumer (DTC) and through healthcare practitioners, Prognora delivers point-of-care results within 5 minutes.

A Biophysics Approach to Early Detection

Genefitletics measures the crosstalk between the oral microbiome, gut microbiome, and mitochondria to identify cardiometabolic diseases at the cellular level before symptoms appear. During its initial consumer phase, the company processed over 100 billion cellular data points across 10,000+ active molecular pathways

The data revealed how microbial stress drives hypermetabolism and allostatic overload, starving longevity pathways and triggering systemic conditions. Prognora successfully flags pre-symptomatic risks for Type 2 diabetes, cardiovascular disease (CVD), gum disease, cognitive decline, and systemic inflammation.

Proprietary AI Models Built for the Indian Population

Backed by seven years of research, four years of commercialisation, and eight internal validation studies, Genefitletics has developed age and gender-stratified AI models tailored to Indian adult men and women. By mapping these high-dimensional datasets to define true baseline biological activity reflecting quantified risk profile of Indian population and combining them with patient-specific clinical phenotypes, the platform delivers:

• Actionable Pathways: Evaluating over 10,000 active molecular pathways.
• Prognostic Biomarkers: Real-time visibility across six primary domains—immune function, oral microbiome, gut microbiome, metabolic health, cognitive health, and nutrient absorption delivered via 45 biological pathway insights
• Precision Interventions: Targeted, disease-modifying recommendations and precision nutrition mapped to a proprietary therapeutic ontology.
• Real-Time Lifestyle Tracking: A built-in "red flag" model showing how daily lifestyle choices immediately impact biological pathways & disease phenotypes.

ORAHYG PRO: Next-Level Cellular Intelligence

Users can upgrade their baseline assessment to ORAHYG PRO, Genefitletics’ fully personalised cellular intelligence test. ORAHYG PRO provides a deeper analysis of individual microbiome–mitochondrial communication, offering hyper-personalized therapeutic strategies to restore cellular physiology and counteract metabolic disruption.

Availability

Prognora and ORAHYG PRO will officially launch on 26 October 2026, offering consumers and clinicians an evidence-based, data-driven approach to pre-disease management.